AACR 2021 | Blinatumomab and inotuzumab in children with R/R B-ALL
Sarah Tasian
• 20 Apr 2021
Sarah K. Tasian, MD, University of Pennsylvania School of Medicine and Abramson Cancer Center, Philadelphia, PA, outlines the use of blinatumomab and inotuzumab for the treatment of children with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The study reported that both blinatumomab and inotuzumab can induce deep remissions in patients with R/R B-ALL and that blinatumomab can be used as an effective bridging therapy during infection. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Sarah K. Tasian, MD, has received research funding from Incyte Corporation, and has participated in scientific advisory boards for Kura Oncology and Aleta Biotherapeutics.
